The 5 Key Questions Addressed by this Report:
- How many physicians were reached by Vimpat through personal promotion in 2016 and how does this compare to its peer set in the Seizure markets?
- What promotional mix was leveraged (e.g., sales rep detailing, physician education, and paid speaking) and what was the median spend on each type of activity?
- How does UCB's depth of coverage vary within key specialties (e.g., Neurology, Internal Medicine, and Critical Care Medicine) and how does this compare to its peers and the overall set of rep-accessible physicians?
- How often are physicians receiving paid meals for Vimpat throughout the year (e.g., monthly, quarterly, annually)?
- Who were the most detailed prescribers and top paid speakers for Vimpat in 2016?
Data Sources and Methodology:
- We leverage company-reported financial transaction data disclosed through CMS Open Payments. This data set captures all transfers of value (e.g., speaking fees, consulting fees, travel, education, and meals) made on behalf of a drug or device manufacturer to a physician. Currently, 42 months of longitudinal data is available - covering payments to more than 900,000 U.S. healthcare professionals.
- Over 15,800 paid interactions across 5,200 physicians made on behalf of Vimpat were carefully examined to support our analysis. In addition, interaction data from 11 peer products (e.g., Aptiom, Banzel, Briviact, Fycompa, Onfi, Oxtellar XR, Qudexy XR, Roweepra, Sabril, Spritam, and Trokendi XR) was leveraged to provide benchmarking and market insights.
For more information about this report visit https://www.researchandmarkets.com/research/vhgdch/vimpat_2016_u_s